INTRODUCTION
============

In subfertile couples, intrauterine insemination (IUI) is often a stop gap treatment while waiting for, or instead of *in-vitro* fertilization (IVF). Although IUI has not been included as an assisted reproductive technique, it has been widely applied emdepirically.[@B1],[@B2] However, the superiority of IUI compared to that of IVF or efficacy of IUI compared to that of expectant management is debatable. In 2009, the European Society of Human Reproduction and Embryology Capri Workshop Group reviewed controversies in IUI on the basis of the available evidence.[@B3] They suggested that compared to expectant management, IUI with stimulation might lead to improved clinical outcomes.[@B4],[@B5] Particularly, ovarian stimulation with gonadotropin may have a moderate benefit compared to clomiphene citrate,[@B5],[@B6] while still being associated with increased cost for the repeated injections, frequent monitoring, risk of multiple pregnancies[@B7],[@B8],[@B9] and development of ovarian hyperstimulation syndrome (OHSS) as a complication.[@B10],[@B11]

The most desirable goal of ovulation induction for IUI is a higher pregnancy rate with reduced complications. To achieve this goal, the use of minimal stimulation has been considered, because it has been reported to reduce complications while maintaining overall pregnancy rates.[@B12] The concept of minimal stimulation was first proposed by Kistner in 1972, who used clomiphene citrate (CC) followed by overlapping human menopausal gonadotropin (hMG) to increase the pregnancy rate compared to the use of CC alone and to reduce the amount of hMG required for stimulation. Since then, research has continued using variable agents combined with various doses and types of gonadotropin. In spite of the heterogeneity of previous studies-ranging from retrospective reviews to prospective randomized controlled studies-investigating minimal stimulation, the clinical pregnancy rates reported were equal or superior to those in gonadotropin-only regimens.[@B13],[@B14] Furthermore, the use of minimal stimulation resulted in fewer stimulation days and less gonadotropin use, suggesting that it is more cost-effective than gonadotropin-only cycles.[@B10],[@B15],[@B16],[@B17]

Although previous studies have reported comparable pregnancy outcomes for IUI using minimal stimulation,[@B6],[@B12],[@B13],[@B14],[@B18] there is lack of evidence regarding the regimen to be selected in the clinical field. This study aimed to identify an efficacious regimen for discrete administration of gonadotropin combined with CC or letrozole (LTZ), to be used in ovulation induction for IUI.

MATERIALS AND METHODS
=====================

The present study was designed as a retrospective comparative study. From January 2008 to March 2013, 257 IUI cycles performed in 158 couples were included in this study. Only patients aged 25-42 years with at least one patent tube were included in this study. The indications for treatment were unexplained infertility, endometriosis or male factor infertility. While most couples had a duration of infertility ≥1 year and underwent a routine infertility workup, some of them had a duration \<1 year, with participating women being aged \>35 years. The following exclusion criteria were adopted: bilateral tubal obstruction, stage III-IV endometriosis, cycles using donor sperm, previous IUI attempts 4 or more, and cycles cancelled due to no ovarian response to ovarian stimulation. This study was approved by the Institutional Review Board at the Severance Hospital, Yonsei University College of Medicine.

All women underwent testing for tubal patency by hysterosalpingography, evaluation of pelvic anatomy by transvaginal ultrasound, and assessment of basal hormones on day 3 of the menstrual cycle. Semen parameters were interpreted using the World Health Organization (2010) criteria. The regimen of ovulation induction was determined based on the previous response or physician\'s preference. A dose of 100 mg/d CC (Clomiphene, Youngpoong Pharma, Seoul, Korea) or 5 mg/d LTZ (Femara, Novartis, Basel, Switzerland) was administered on days 3-5 of the menstrual cycle for 5 days. In combination with their fixed schedule for CC or LTZ, patients received two different regimens of hMG, (IVF-M, LG Life Sciences, Seoul, Korea), either 150 IU administered on day 6 and 8 of the menstrual cycle (2-day regimen, on alternate days) or 150 IU administered on days 5, 7, and 9 of the menstrual cycle (3-day regimen, on alternate days). A total of 257 cycles were divided into 2 main groups based on the fixed schedule treatment: the CC group (n=126) or LTZ group (n=131). Each group was further divided into two subgroups according to the alternate-day regimen of gonadotropin used: CC combined with a 2-day regimen (CC+300 group, n=37) or 3-day regimen (CC+450 group, n=89), and LTZ combined with a 2-day regimen (LTZ+300 group, n=36) or 3-day regimen (LTZ+450 group, n=95). The luteinizing hormone (LH) surge was tested using LH2 kits (Bayer Corporation, Tarrytown, NY, USA). When the mean diameter of the leading follicle reached 17-18 mm, an injection of 10000 IU of urinary human chorionic gonadotropin (hCG) (IVF-C, LG Life Sciences, Seoul, Korea) or 250 µg of recombinant hCG (Ovidrel, Serono, Geneva, Switzerland) was administered intramuscularly or subcutaneously. IUI was performed 38 h after hCG administration. If the urinary LH surge test was positive, the insemination was performed the day after detection of the spontaneous LH surge, following the hCG injection.

The semen samples were microscopically examined to determine sperm motility and concentration after 30 minutes of liquefaction at room temperature. Sperm samples for IUI were prepared by density gradient centrifugation. For the insemination process, a soft catheter (Wallace artificial insemination catheter, Smiths Medical, London, UK) was used to introduce 0.5 mL of the prepared semen into the uterine cavity. After insemination, luteal support was achieved with micronized progesterone vaginal suppositories (Utrogestan, Cassenne-Aventis, Paris, France), 400 mg daily for 2 weeks.

The primary outcome measures were achievement of pregnancy, multiple pregnancy, and OHSS development. The secondary outcome measures were the size of the leading follicle, endometrial thickness on the day of hCG administration, and number of growing and mature follicles. Clinical pregnancy was defined as the presence of an intrauterine gestational sac with a pulsating fetal heart beat on ultrasound. Multiple pregnancy was defined as the presence of \>2 intrauterine gestational sacs with a pulsating fetal heart beat on ultrasound. OHSS was classified as mild, moderate, severe, and critical according to criteria described previously by Navot, et al.[@B19]

Data were analyzed using the SPSS software package, version 20.0 (IBM Inc., Armonk, NY, USA) by Student t-test and one-way ANOVA to compare means for normally distributed continuous variables. The Mann-Whitney U test was used for non-parametrically distributed variables. Fisher\'s exact test and the chi-square test were used for categorical variables. Univariate and multivariate logistic regression analyses were also performed. Sample size calculation was not performed since the study was designed as retrospective comparative study based on chart review. A *p* value \<0.05 was considered statistically significant.

RESULTS
=======

There were no significant differences between the 4 groups in terms of the women\'s age, duration of infertility, percentage of primary infertility, causes of infertility, and tubal patency. However, there was a significant difference in basal serum follicle-stimulating hormone (FSH) levels among the 4 groups, with the post hoc analysis showing significantly higher basal serum FSH levels in the LTZ+450 group compared to the CC+300 group (6.66±2.09 vs. 8.75±3.81, *p*=0.021). Furthermore, the number of previous IUI attempts was significantly different among the 4 groups, with the post hoc analysis showing a significantly higher number of previous IUI attempts in the LTZ+300 group compared to the CC+300 group (0.21±0.48 vs. 0.92±0.97 months, *p*=0.008) and in the LTZ+450 group compared to the CC+450 group (0.55±0.80 vs. 1.20±1.14, *p*\<0.001) ([Table 1](#T1){ref-type="table"}).

The clinical pregnancy rate, multiple pregnancy rate, and the development of OHSS per cycle in the study population were 15.2%, 20.5%, and 5.8%, respectively. The clinical pregnancy rate was comparable between the CC and LTZ groups (18.3% vs. 12.2%, *p*=0.177). Multiple pregnancies occurred in 2 cases in the CC group and 6 cases in the LTZ group (8.7% vs. 37.5%, *p*=0.028), for a total of 7 twin and 1 triplet pregnancies. OHSS was significantly more prevalent in the CC group than in the LTZ group \[13 cases (10.3%) vs. 2 cases (1.5%), p=0.003\]. The size of the leading follicle and the number of follicles with a mean diameter of ≥18 mm on the day of hCG administration were comparable between the two groups. However, on the day of hCG administration, the number of follicles with a mean diameter 11-13 mm was significantly higher (0.93±1.27 vs. 0.49±0.83, *p*=0.001) and endometrial thickness was significantly lesser in the CC group (9.37±2.02 vs. 9.98±1.85, *p*=0.005) than the LTZ group. Although there was no difference in total motile sperm count (TMSC) before preparation between the two groups, the post-preparation sperm concentration was significantly higher in the LTZ group than in the CC group ([Table 2](#T2){ref-type="table"}).

In the cycles using CC, the primary and secondary outcomes were comparable between the alternate-day gonadotropin regimens of 2 and 3 days. However, the endometrial thickness on the day of hCG administration was significantly greater in the alternate-day regimen of 3 days compared to that of 2 days (8.77±2.11 mm vs. 9.62±1.94 mm, *p*=0.031). In the cycles using LTZ, the primary outcomes-clinical pregnancy rate, multiple pregnancy rate, and development of OHSS-and the secondary outcomes were similar between both alternate-day gonadotropin regimens ([Table 3](#T3){ref-type="table"}).

In the alternate-day gonadotropin regimen of 2 days, the primary and secondary outcomes were comparable between the CC+300 and LTZ+300 groups. However, the number of follicles in size of 11-13 mm on the day of hCG administration was significantly higher in CC+300 group than LTZ+300 group (0.78±1.06 vs. 0.35±0.65, *p*=0.041). In the alternate gonadotropin regimen of 3 days, although there was no significant difference in the clinical pregnancy rate between the cycles using CC and LTZ, the endometrial thickness was significantly greater in the LTZ+450 group (9.62±1.94 mm vs. 10.14±1.79 mm, *p*=0.049). The number of follicles in size of 11-13 mm on the day of hCG administration was significantly higher in the CC+450 group than in the LTZ+450 group (0.99±1.34 vs. 0.54±0.89, *p*=0.009). The pre-preparation TMSC and post-preparation sperm concentrations were significantly higher in the LTZ+450 group than in the CC+450 group (106.12±130.06 vs. 152.57±142.91, *p*=0.024; 56.15±59.62 mL vs. 103.47±107.14 mL, *p*\<0.001). OHSS was significantly more prevalent in the CC+450 group than in the LTZ+450 (12.4% vs. 1.1%, *p*=0.002). Finally, the multiple pregnancy rate was significantly higher in the LTZ+450 group than in the CC+450 group (50% vs. 13.3%, *p*=0.038) ([Table 3](#T3){ref-type="table"}).

DISCUSSION
==========

The four different regimens in our study showed comparable clinical pregnancy rates per cycle. Minimal stimulation protocols using LTZ resulted in the development of fewer small follicles, with a similar number of medium- to large-sized follicles when compared to those using CC. As a result, the development of OHSS was more prevalent in CC users, especially combined with alternate-day gonadotropin 3 days regimen. Multiple pregnancies were more prevalent in the alternate-day gonadotropin regimen of 3 days, combined with LTZ, but not in the alternate-day gonadotropin regimens of 2 days, neither in combination with CC, nor LTZ.

The clinical pregnancy and multiple pregnancy rates in the current study are comparable to those reported in previous studies.[@B4],[@B15],[@B20],[@B21],[@B22],[@B23],[@B24],[@B25] In large population observational studies[@B26],[@B27] and a randomized controlled trial,4 although the clinical pregnancy rate per cycle was approximately 10% in IUI with gonadotropin only, multiple pregnancies represented 30% of these cases. In other studies, the multiple pregnancy rate after ovulation induction with gonadotropin varies between 5% and 20%.[@B4],[@B23],[@B25],[@B28] In terms of OHSS, few studies have demonstrated the development of OHSS in IUI with controlled ovarian stimulation cycles. In a prospective randomized trial, the cancellation rate was reported based on the OHSS risk, instead of the OHSS development rate in IUI with gonadotropin stimulation (cancellation rate, 1.2% vs. 8.4%, respectively).[@B29] In a prospective randomized study which compared conventional CC/hMG stimulation protocol to minimal stimulation protocol, the incidence of OHSS was 3% in conventional stimulation cycles whereas none of OHSS was developed in minimal stimulation cycles.[@B10] Fewer OHSS cases were observed in our study than in previous studies[@B10],[@B11] of IUI cycles with minimal stimulation.

Interestingly, in our study, multiple pregnancies significantly increased in cycles with the alternate-day regimens of 3 days, in LTZ users. Although it cannot be clearly explained, this significant difference may be due to superovulation by combining gonadotropin and favorable endometrial receptivity by using LTZ without antiestrogenic effect on endometrium. LTZ itself has been suggested to develop less multiple pregnancies in ovulation induction for polycystic ovary syndrome (PCOS) women.[@B30] However, our study showed that superovulation combined with gonadotropin may increase multiple pregnancies. Recently, a large retrospective review of 2929 patients with unexplained infertility showed that increasing number of mature follicles gradually increased multiple pregnancies.[@B31] Furthermore, contrary to CC, LTZ has no antiestrogenic effect on endometrium. Our study showed that minimal stimulation combined with LTZ increased endometrial thickness compared to that combined with CC, which may indicate that the administration of CC cause hostile endometrium due to antiestrogenic effect on endometrium.

The current study showed that OHSS development was significantly lower in the LTZ group, independent of other factors such as endometrial thickness, total amount of gonadotropin, follicular number on the day of hCG administration, or multiple pregnancy (data not shown). Increasing development of OHSS in CC users can result from increased development of small size follicles than LTZ users. Regimens using CC comparing to LTZ in 3 days regimen resulted in significantly increased development of small-sized follicles (11-14 mm) with a similar number of medium- (15-17 mm) to large-sized follicles (≥18 mm); this change may result in increased levels of estradiol and contribute to more development of OHSS. In 2 days regimen, however, difference of small-sized follicles (11-14 mm) between CC and LTZ was not significant, although the actual number was higher in CC group, which might be arised from small number of subjects compared to 3 days regimen. Compared to other studies, however, there are few data showing OHSS development in ovulation induction using for IUI cycles. In a recent systemic review of aromatase inhibitor use in ovulation induction for PCOS women, 9 randomized controlled trials assessed OHSS development between various protocol using LTZ, clomiphene combined with timed intercourse or IUI. The review showed few occurrences of OHSS in most of the studies; only 2 events of OHSS was reported in clomiphene 100 mg group in a study from Indian group. They concluded no evidence for a difference in frequency of OHSS between LTZ and CC with or without adjuncts. However, it is noteworthy that, among the 9 trials, only 3 trials compared the effect of LTZ and clomiphene in ovulation induction for IUI cycle, and adjuncts with gonadotropin was in one trial.[@B30]

In the previous studies, LTZ has been shown to be neither superior nor inferior to CC, in terms of outcomes described above;[@B30],[@B32] except reports which have suggested advantages in PCOS patients with CC resistance allowing ovulation induction.[@B33],[@B34] Because of the suggested advantages, though off label, comparable outcomes after ovulation induction of LTZ have led to the use of LTZ as an alternative agent.[@B14],[@B35] To our knowledge, this is the first study demonstrating the superiority of LTZ over CC, in terms of less developed OHSS with comparable pregnancy rate, when administered in combination with gonadotropin in IUI cycle. Although, there was an increased risk of multiple pregnancy rate in LTZ+450 group in the present study, there was no multiple pregnancy in LTZ+300 group. To reduce multiple pregnancy rate, therefore, lower doses of gonadotropin may be preferred in minimal stimulation protocol using LTZ.

Several limitations of the present study should be mentioned. Firstly, since this was a retrospective study and not a randomized controlled trial, a selection bias or confounding factors may influence the results. However, the similarity in baseline clinical characteristics-including age, duration of infertility, and causes of infertility-suggest that the selection bias was minimal. Secondly, the sample size has limited statistical power for any conclusion to be drawn regarding the outcomes among 4 different groups. When a power calculation was performed using PS: Power and Sample size calculation software Version 3.0.43 (<http://biostat.mc.vanderbilt.edu/wiki/Main/PowerSampleSize>), the sample size has the power of 27.5, 58.9, and 85.5% to detect a significant difference for clinical pregnancy rate, multiple pregnancy rate and the development of OHSS, respectively, between the CC group and the LTZ group. Regarding the development of OHSS, further studies in a larger scale will be necessary to confirm our results, although this study had sufficient power

In conclusion, a minimal stimulation protocol using LTZ combined with alternate-day administration of gonadotropin for 2 days seems to be efficacious for IUI, because it does not affect superovulation and clinical pregnancy rates, while reducing multiple pregnancies and OHSS development.
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CC, clomiphene citrate; LTZ, letrozole; FSH, follicle-stimulating hormone; IUI, intrauterine insemination.

Values represent mean±SD.

^\*^,^†^,^‡^,^§^Post-hoc *p*\<0.05 by Bonferroni\'s multiple comparison test.

^\*^CC300 vs. LTZ 450.

^†^CC300 vs. LTZ300.

^‡^CC300 vs. LTZ 450.

^§^CC450 vs. LTZ450.
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The Outcomes of Intrauterine Insemination Cycles Using Gonadotropin Combined with Clomiphene Citrate or Letrozole
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CC, clomiphene citrate; ET, endometrial thickness; OHSS, ovarian hyperstimulation syndrome; TMSC, total motile sperm count; hCG, human chorionic gonadotropin.

Values represent mean±SD.
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The Outcomes of IUI Cycles Using Four Regimens
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CC, clomiphene citrate; LTZ, letrozole; TMSC, total motile sperm count; OHSS, ovarian hyperstimulation syndrome; IUI, intrauterine insemination.
